Alterations of microRNAs expression profile induced by oncogenic Ras by D'Amato, Valentina
Università degli Studi di Napoli Federico II 
Dipartimento di Biologia e Patologia Cellulare e 
Molecolare “L. Califano” 
 
 
 
 
 
 
 
Doctorate School in Molecular Medicine 
 
PhD Program in 
Genetics and Molecular Medicine 
Coordinator: Prof. Lucio Nitsch 
XXIII Cycle 
 
 
 
 
Alterations of microRNAs expression profile 
induced by oncogenic Ras 
 
 
 
 
 
 
Supervisor:             PhD student: 
Ch.mo Prof. Roberto Di Lauro                 Dr. Valentina D’Amato 
 
Co-Supervisor: 
Dott.ssa Gabriella De Vita 
  2 
Ph.D. in Genetics and Molecular Medicine 
Members 
 
Prof. Stefano Bonatti  
Dipartimento di Biochimica e Biotecnologie 
Mediche, Università di Napoli 
 
Prof. Carmelo Bruno Bruni 
Dipartimento di Biologia e Patologia Cellulare e 
Molecolare “L. Califano” Università di Napoli 
 
Prof. Roberto Di Lauro  
Dipartimento di Biologia e Patologia Cellulare e 
Molecolare “L. Califano” Università di Napoli 
 
Prof. Paola Di Natale  
Dipartimento di Biochimica e Biotecnologie 
Mediche, Università di Napoli 
 
Prof. Pierpaolo Di Nocera 
Dipartimento di Biologia e Patologia Cellulare e 
Molecolare “L. Califano” Università di Napoli 
 
Prof. Maria Furia 
Dipartimento di Genetica, Biologia Strutturale e 
Funzionale, Università di Napoli 
 
Prof. Girolama La Mantia  
Dipartimento di Genetica, Biologia Strutturale e 
Funzionale, Università di Napoli 
 
Prof. Luigi Lania  
Dipartimento di Genetica, Biologia Strutturale e 
Funzionale, Università di Napoli 
 
 
Prof. Lucio Nitsch  
Dipartimento di Biologia e Patologia Cellulare e 
Molecolare “L. Califano” Università di Napoli 
 
  3 
 Prof. Lucio Pastore  
Dipartimento di Biochimica e Biotecnologie 
Mediche, Università di Napoli 
 
Prof. John Pulitzer Finali 
Dipartimento di Biologia Strutturale e Funzionale, 
Università di Napoli 
 
Prof. Fabio Rossano  
Dipartimento di Biologia e Patologia Cellulare e 
Molecolare “L. Califano” Università di Napoli 
 
 Prof. Tommaso Russo 
 Dipartimento di Biochimica e Biotecnologie 
Mediche, Università di Napoli 
 
Prof. Lucia Sacchetti  
Dipartimento di Biochimica e Biotecnologie 
Mediche, Università di Napoli 
 
Prof. Francesco Salvatore 
Dipartimento di Biochimica e Biotecnologie 
Mediche, Università di Napoli 
 
 Prof. Paola Salvatore  
Dipartimento di Biologia e Patologia Cellulare e 
Molecolare “L. Califano” Università di Napoli 
 
 Dr. Maria Stella Zannini  
Primo Ricercatore CNR 
Dipartimento di Biologia e Patologia Cellulare e 
Molecolare “L. Califano” Università di Napoli 
 
 Prof. Chiara Zurzolo  
Dipartimento di Biologia e Patologia Cellulare e 
Molecolare “L. Califano” Università di Napoli  
    
  4 
INDEX 
 
 
Abbreviations  5 
Abstract  6 
1. Introduction  8 
1.1 MicroRNAs  8 
1.2 Genomic localization of microRNAs  8 
1.3 MicroRNA biogenesis  9 
1.4 microRNA function  12 
1.5 microRNAs: tumour suppressors and oncogenes  14 
1.6 Thyroid cancer  15 
1.7 miRNA in Thyroid Cancer  16 
1.8 Role of Ras oncogenes  19 
1.9 Ras genes  20 
1.10 Ras proteins signal transduction pathways  22 
1.11 The FRTL-5 thyroid cell line  24 
1.12 Transformation of FRTL-5 cells by Ras oncogene  24 
2. Aim of the Study  26 
3. Materials and methods  27 
3.1 Cell culture.  27 
3.2 Vectors.  27 
3.3 Transfections.  28 
3.4 Chromatin Immuno-Precipitation (ChIP)  29 
3.4.1 Crosslinked chromatin preparation.  29 
3.4.2 Transcription rate measurement.  29 
3.5 RNA extraction and Real-Time PCR.  30 
3.6 Protein studies.  32 
3.7 Immunoblot.  32 
3.8 Proliferation analysis.  32 
3.9 Motility assay.  33 
4. Results and Discussion  34 
4.1 Screening of microRNA regulated by Ras.  35 
4.2 Generation of miR135a over expressing clones.  38 
4.3 Functional studies of miR135a.  39 
4.3. 1. miR135a and Proliferation  40 
4.3. 2. miR135a and Differentiation.  42 
4.3. 3. miR135a and Cell Motility.  44 
4.4 Regulation of miR-21 is cell-type specific.  47 
4.5 miR21 induction by Ras in FRTL-5 is mediated by transcriptional 
regulation.  48 
4.6 miR21 promoter is responsive to oncogenic Ras expression.  50 
4.7 Identification of miR21 regulatory regions responsive to Ras.  51 
5. Conclusion  54 
  5 
6. Bibliography  55 
7. Acknowledgement  64 
  
Abbreviations  
  
  
   The abbreviations used are: microRNA, miRNA; Papillary carcinoma, PC; 
Follicular carcinoma, FC; poorly differentiated carcinoma, PDC; anaplastic 
carcinoma, AC; Medullary carcinoma, MC; Follicular thyroid cell, TFC; 
Follicular Rat thyroid epithelial cell line, FRTL-5; Oncogenic human h-ras 
(G12V) fused to the ERTM Ligand binding domain, ER-RasV12; FRTL5 
derived stable cell line expressing ER-RasV12, Cl11; FRTL5 derived stable 
cell lines expressing oncogenic human h-ras (G12V), RasV12 clones (V27, 
V29 or V39); Tamoxifen, 4OHT;  Thyroperoxidase, TPO; Sodium-Iodide 
symporter, NIS; TSH receptor, TSHr; thyroglobulin, Tg; V29 derived stable 
cell lines expressing miR135a, miR135a clones.  
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Abstract   
   Literature emphasizes the key role of miRNAs in cancer development. 
Moreover it has been demonstrated that oncogenes and tumorsuppressors can 
act also by regulating the expression of specific miRNAs. Previous results 
published by Landgraf et al., using the FRTL-5 ER-H-RasV12 inducible system 
highlighted that Ras is able to induce aberrant expression of microRNAs 
during the transformation of thyroid epithelial cells. Taking advantage of the 
inducible system FRTL-5 ER-H-RasV12 we decided to study the miRNAs 
involved in Ras-induced transformation. The aim of my project was to identify 
Ras-regulated miRNAs and study their functional or transcriptional role in 
transformation of thyroid epithelial cells. 
We decided first to validate the Landgraf’s libraries data by Real-Time PCR, 
later we selected microRNAs of interest to study their functional role in Ras-
induced transformation. We measured the level of expression of miR15b, 
miR16, miR27a, miR27b, miR29b, miR99b, miR135a, miR135b, miR324-5p 
in inducible systems FRTL-5 ER-Ras clone (Cl11) treated with 4OHT for 24h, 
48h, 72h, 96h and 7days, in FRTL-5 parental cell line and in FRTL-5 clones 
constitutively expressing human H-RasV12.  
From the screening by Real-Time PCR we identified two microRNAs 
particularly regulated by oncogenic Ras: miR135a resulted down-regulated in 
chronically transformed cells by Ras oncogene meanwhile miR21 resulted up-
regulated by Ras oncogene in the inducible system.  
We over expressed miR135a in the chronically transformed FRTL-5 H-RasV12 
clone V29 to test the possibility that miR135a rescue could interfere with at 
least one of the phenotypes induced by oncogenic Ras. We proceeded to 
analyze proliferation, differentiation and cell motility of FRTL-5 RasV12 
miR135a cells. We observed a little reduction of proliferation and migration in 
miR135a clones compared to FRTL-5 RasV12. 
It is known that Ras is able to promote miR21 expression in an epithelial 
system we asked if this regulation was cell-type specific. The Real-Time PCR 
results highlights that even though the two inducible systems analyzed (FRTL-
5 ER-Ras and NIH ER-Ras) have a different basal level of miR21, in NIH ER-
Ras cells 4OHT treatment do not lead to a significant increase of miR21, 
suggesting that Ras-induced miR21 up-regulation is cell-type specific. Once 
established the effects of oncogenic Ras on mature miR21 expression the 
following step was to study the mechanism through which this regulation takes 
place. Our data obtained by Real-Time PCR and chromatin immuno-
precipitation (ChIP) suggests that miR21 induction by Ras in FRTL-5 cells is a 
transcriptional phenomenon. By luciferase assay we analyzed the miR21 
promoter responsive to Ras oncogene and we verified if also its activation was 
cell-type specific. To this purpose we used FRTL-5, NIH3T3 and Rat2 cell 
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lines. The data obtained suggests that even though oncogenic Ras is able to 
lightly regulate the activity of miR21 promoter in fibroblasts, the activation 
displayed in FRTL-5 is much stronger and significant. The final step was the 
identification of potential regulatory regions, aside from the promoter already 
identified, responsive to oncogenic Ras.  
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1. Introduction  
1.1 MicroRNAs  
 
   MicroRNAs (miRNAs) are endogenous non-coding RNAs of about 22 
nucleotides, regulating genes in animals and plants by pairing to the 3’UTR 
regions of messenger RNAs (Zeng et al. 2002) of target genes and specifying 
mRNA cleavage or repression of protein synthesis. There is increasing 
evidence that miRNAs have an important regulatory role in a broad range of 
biological processes, including cellular differentiation, proliferation, apoptosis 
and cancer development (Bartel 2004). After the initial genetic discovery in 
nematodes (Lee et al. 1993), it was soon confirmed that all investigated higher 
eukaryotes, including plants and mammals, contain miRNA genes (Ambros et 
al. 2003). miRNA genes represent only a small part of the genome (3%), but 
they regulate approximately from 20% to 30% of all human genes and there is 
an average of 200 predicted targets per miRNA (Carthew 2006).  
The microRNAs discovery has been an exciting breakthrough in Biological 
Sciences of the past decade, culminating in Nobel Prize in Physiology or 
Medicine awarded to Andrew Fire and Craig Mello. Building on previous work 
mainly in plants (Lindbo et al. 1993), Fire discovered that exogenous double-
stranded RNA can be used to specifically interfere with gene function. This 
phenomenon was called RNA interference (RNAi) (Fire et al. 1998). They also 
speculated that organisms might use double-stranded RNA naturally as a way 
of silencing genes. It was then shown that RNA interference was mediated by 
22 nucleotide single-stranded RNAs termed small interfering RNAs (siRNAs) 
derived from the longer double-stranded RNA precursors (Zamore et al. 2000). 
Computational predictions of miRNA targets suggest that up to 30% of human 
protein coding genes may be regulated by miRNAs (Rajewsky 2006). This 
makes miRNAs one of the most abundant classes of regulatory genes in 
humans. MicroRNAs are now perceived as a key layer of post-transcriptional 
control within the networks of gene regulation.  
 
 
 
 
1.2 Genomic localization of microRNAs 
 
   Micro-RNAs are initially transcribed as precursor molecules in the nucleus, 
where many are organized in genomic cluster, while others exist as individual 
genes. Besides miRNAs that are non linked to any other transcription unit, it 
has been reported that miRNA genes are located in exons or introns of non-
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coding genes (Rodriguez et al. 2004), as well as protein-coding genes 
(Smalheiser 2003). Expression studies on miRNAs and host mRNAs revealed 
that miRNAs are frequently co-expressed with their host genes (Baskerville 
and Bartel 2005). About a quarter of the human miRNAs genes are in the 
introns of pre-mRNAs. These are preferentially in the same orientation as the 
predicted mRNAs, suggesting that most of these miRNAs are not transcribed 
from their own promoters but are instead processed from introns. This 
arrangement provides a convenient mechanism for the coordinated expression 
of a miRNA and a protein (Lagos-Quintana et al. 2003).   
Some mammalian miRNA genes are located in repetitive genomic regions as 
well, and it has been suggested that repetitive elements such as transposons 
may be the driving force that creates new miRNAs during mammalian 
evolution (Smalheiser and Torvik 2005).   
MicroRNAs can be grouped into families on the basis of sequence homology, 
which is found primarily at the 5′ end of the mature miRNAs, but whether 
members of the same miRNA family control similar biological events remains 
to be seen. Many miRNAs are evolutionarily conserved from worms to 
humans, which implies that these miRNAs direct essential processes both 
during development and in the adult body (Esquela-Kerscher and Slack 2006).  
 
 
 
 
1.3 MicroRNA biogenesis  
 
   The maturation of microRNA is a multi-step process that begins in the 
nucleus and ends in the cytoplasm (Novina and Sharp 2004) (Figure 1). 
Analyses have shown that human primary miRNA transcripts (pri-miRNAs) 
contain cap structures as well as poly (A) tails which are the unique properties 
of class II gene transcripts. These data indicate that pol II is the main RNA 
polymerase for miRNA gene transcription (Lee et al. 2004).  
Animal miRNAs are initially transcribed as part of a long RNA precursor, 
defined as “primary miRNA” (pri-miRNA). Within the pri-miRNA, the ~22-nt 
mature miRNA forms part of one arm of a ~80-nt imperfect stem-loop 
sequence (Cullen 2004). The first step is the nuclear cleavage of the pri-
miRNA, which liberates a ~60-70nt stem loop intermediate, known as pre-
miRNA (Zeng 2006). This processing is performed by Drosha, an RNase III-
type endonuclease that contains two RNase III domains and a dsRNA binding 
domain in the C-terminal half, a proline-rich domain and an argininerich (R-
rich) domain in the N-terminal half of the protein. It cleaves both strands of 
stem at sites near the base of the primary stem loop, leaving a 5’ phosphate and 
a 2-nt 3’ overhang (Basyuk et al. 2003). It has been demonstrated that for a pri-
miRNA to be efficiently processed by Drosha the targeted hairpin must consist 
of a large terminal loop of ≥10 nt and a stem region somewhat longer than the 
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one present in the final pre-miRNA (Zeng and Cullen 2005). The class 3 
RNase III Drosha forms a complex (microprocessor) with a double-stranded 
RNA-binding protein, termed DGCR8 in humans and Pasha in flies and worms 
(Han et al. 2004). Cleavage of a pri-miRNA by microprocessor begins with 
DGCR8 recognizing the ssRNA-dsRNA junction typical of a pri-miRNA. 
Then, Drosha is brought close to its substrate through interaction with DGCR8 
and cleaves the stem of a pri-miRNA ~11 nt away from the two single stranded 
segments (Han et al. 2006). Although microprocessor is already sufficient for 
conversion of a pri-miRNA into a pre-miRNAs in vitro, cleavage of pri-
miRNA in vivo does not depend on Drosha and DGCR8 only, but also on other 
accessory proteins, such as the RNA binding protein hnRNP A1 and the p68 
and p72 RNA helicases. A subclass of pre-miRNAs, pre-miRNA/introns 
(mirtrons), have recently been shown to depend on the RNA splicing 
machinery for their biogenesis in Drosophila, Caenorhabditis elegans and 
mammals (Berezikov et al. 2007). Mirtrons are derived from certain 
debranched introns that fold into hairpin structures with 5′ monophosphates 
and 3′ 2-nt hydroxyl overhangs, which mimic the structural hallmarks of pre-
miRNAs and enter the miRNA processing pathway (Okamura et al. 2007; 
Ruby et al. 2007). The discovery of mirtrons suggests that any RNA, with a 
size comparable to a pre-miRNA and all the structural features of a pre-
miRNA, can be utilized by the miRNA processing machinery, and potentially 
give rise to a functional miRNA.  
After initial nuclear processing, the pre-miRNA is exported to the cytoplasm 
by the export receptor Exportin-5 (Exp-5). This step is a Ran-dependent and 
requires the hydrolysis of GTP (Yi et al. 2003). The interaction of Exportin-5 
with the pre-miRNA requires a 3’ overhang and the stem of the precursor for 
efficient export (Zeng and Cullen 2004). Exp-5 is also important for stabilizing 
pre-miRNAs in the nucleus. When Exp-5 is knocked down by siRNAs, the 
levels of pre-miRNAs are reduced not only in the cytoplasm, but also in the 
nucleus, suggesting that binding of pre-miRNAs to Exp-5 protects them from 
degradation (Yi et al. 2003).   
In the cytoplasm, another RNAse III endonuclease termed Dicer is responsible 
for dicing pre-miRNAs into short RNA duplexes termed miRNA duplexes 
(Bernstein et al. 2001). The RNA strand of the miRNA duplex that is 
complementary to the mature miRNA is depicted with a star symbol 
(miRNA*). In addition to two RNase III signature domains, mammalian Dicer 
has a N- terminal ATPase/helicase domain, a DUF 283 domain, a PAZ domain 
and a C-terminal dsRNA binding domain (dsRBD) (Provost et al. 2002). 
Biochemical experiments have revealed that both PAZ domain and dsRBD are 
essential for the interaction of Dicer with pre-miRNAs and long dsRNAs. PAZ 
domain functions in recognizing the 2-nt 3′ overhang signature generated by 
Drosha, while dsRBD is critical for binding long dsRNAs. After capturing pre-
miRNAs or long dsRNAs with its PAZ domain and dsRBD, Dicer dimerizes its 
two RNase III domains intra-molecularly to form a single processing center, 
and cuts the stem of pre-miRNAs or long dsRNAs ~22 nt away from their 
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termini at positions separated by 2 nts, which generates 3′ 2-nt termini (Zhang 
et al. 2004). After Dicer processing, the miRNA duplex is unwound and the 
mature miRNA binds to an Argonaute (Ago) protein in a process that is 
referred to as miRNA loading or assembly, while the miRNA* is degraded. 
The Argonaute family is a diverse family of proteins, each containing 
characteristic domains termed PAZ and PIWI. The Argonaute family can be 
phylogenetically divided into the Ago and Piwi protein families based on 
similarities to Arabidopsis AGO1 and Drosophila Piwi proteins, respectively 
(Carmell et al. 2002). miRNAs bind Ago proteins whereas Piwi proteins bind a 
newly discovered class of small RNAs known as piwi-interacting RNAs 
(piRNAs), which are almost exclusively expressed in the germline  (Aravin et 
al. 2007; Kim 2006). Humans and mice contain four Ago proteins (Ago1–4). 
Structural and biochemical analyses have shown that the ~130- amino-acid 
PAZ domain contains an oligonucleotide- binding fold that allows the protein 
to bind the single-stranded 2-nt 3′ terminal overhangs characteristic of small 
RNAs processed by Dicer (Lingel et al. 2004).  
The miRNA/Ago ribonucleoprotein that is formed represents the core 
component of the effector complexes that mediate miRNA function and is 
known as miRNP (Mourelatos et al. 2002). A primary determinant of which 
the two strands of a miRNA duplex or a siRNA duplex will be loaded on Ago 
proteins is the inherent thermodynamic asymmetry of the miRNA or siRNA 
duplex. The RNA strand whose 5′ end is less stably bound to the opposite 
strand will be loaded to Ago proteins and forms the mature miRNA or siRNA 
(Tomari and Zamore 2005).  
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Figure 1 
 
 
 
The biogenesis of microRNAs. miRNA genes are generally transcribed by RNA 
Polymerase II (Pol II) in the nucleus to form large pri-miRNA transcripts, which are 
capped (7MGpppG) and polyadenylated (AAAAA). These pri-miRNA transcripts are 
processed by the RNase III (Drosha-Pasha), to release the pre-miRNA (~70nt). RAN–
GTP and exportin 5 transport the pre-miRNA into the cytoplasm. RNase III enzyme 
(Dicer) processes the pre-miRNA to generate a transient ~22nt miRNA:miRNA* 
duplex. This duplex is then loaded into the miRISC (light blue). The mature miRNA 
then binds to complementary sites in the mRNA target. miRNAs that bind to mRNA 
targets with imperfect complementarity block target gene expression at the level of 
protein translation (lower left). miRNAs that bind to their mRNA targets with perfect 
(or nearly perfect) complementarity induce target-mRNA cleavage (lower right). 
(Aurora Esquela-Kerscher and Frank J. Slack Nature reviews Cancer vol 6 April 
2006). 
 
 
 
 
1.4 microRNA function  
 
   miRNAs base-pair with miRNA recognition elements (MREs) found in their 
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mRNA targets, typically in the 3′UTR region, and deposit their bound Ago 
proteins onto mRNA targets. The result is translational repression of the 
targeted mRNA, often followed by mRNA destabilization or endonucleolytic 
cleavage of the targeted mRNA. The exact molecular function is dependent 
upon how extensive the complementarity of the miRNA or siRNA is with its 
mRNA target and which Ago protein is deposited on the mRNA target.  
If an miRNA or siRNA bound to Ago2 pairs with extensive complementarity 
with a mRNA target, then the mRNA is cleaved at a position across from 
nucleotides 10 and 11 of the miRNA (or siRNA), while the miRNA remains 
intact (Liu et al. 2004). This cleavage event produces 5′-phosphate and 3′- 
hydroxyl terminal products, characteristic of other RNase H-like enzymes 
(Martinez and Tuschl 2004). The target mRNA is subsequently degraded via 
routine cellular pathways. Experimental and bioinformatics approaches have 
shown that the most important determinant of target RNA recognition by a 
miRNA is perfect or near-perfect complementarity between the proximal (5′) 
region of the miRNA and the mRNA, also known as the “seed” region or the 
“nucleus” (Lai 2002). Initial studies suggested that miRNA-mediated 
translational repression occurred at a step following the initiation of translation 
(Seggerson et al. 2002). More recent studies have lent additional support to the 
model of miRNA mediated repression occurring at a post-initiation step 
(Petersen et al. 2006). miRNA mediated translational repression results in 
decreased levels of the targeted protein. Thus, the model of miRNA function 
occurring at a post-initiation step would require the release of and subsequent 
destruction of the resulting polypeptide (Nottrott et al. 2006).  
Target mRNAs are recognized by miRNAs in the form of ribonucleoprotein 
complexes (miRNPs), through sequence complementarity, usually between the 
miRNA and sequences in the 3′-UTR of the mRNA. The interaction between 
the miRNP and the mRNA can have direct and indirect effects on translation. 
Direct effects occur either through inhibition of initiation of translation, which 
results in prevention of ribosome association with the target mRNA, or through 
inhibition of translation post-initiation. In the case of post-initiation repression 
– which includes premature ribosome drop off, slowed or stalled elongation, 
and cotranslational protein degradation – the repressed mRNA seems to be 
present in polysomes. In addition to direct effects on translation (or protein 
accumulation), miRNPs can have other effects on targeted mRNAs, including 
promoting de-adenylation, which might result in degradation (increased 
turnover). Both de-adenylation and degradation might take place in P bodies 
(denoted by P), which are cytoplasmic foci enriched for factors involved in 
mRNA degradation. It is possible that miRNA-targeted mRNAs could be 
sequestered from the translational machinery and degraded or stored for 
subsequent use. Alternatively, targeted mRNAs might be sequestered as a 
consequence of inhibition of initiation of translation. (Figure 2).  
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Figure 2 
 
Mechanism of miRNA Function The interaction between the miRNP and the mRNA 
can have direct and indirect effects on translation. Direct effects occur either through 
inhibition of initiation of translation, or through inhibition of translation post-initiation 
which includes premature ribosome drop off, slowed or stalled elongation, and 
cotranslational protein degradation Indirect effects on translation: de-adenylation, both 
might take place in P bodies. (Yoontae Lee et al. EMBO J. 2004). 
 
 
1.5 microRNAs: tumour suppressors and oncogenes  
   microRNAs can function as tumour suppressors and oncogenes (Figure 3). In 
normal tissues, proper microRNA (miRNA) transcription, processing and 
binding to complementary sequences on the target mRNA results in the 
repression of target-gene expression through a block in protein translation or 
altered mRNA stability. The overall result is normal rates of cellular growth, 
proliferation, differentiation and cell death. The reduction or deletion of a 
miRNA that functions as a tumour suppressor leads to tumour formation. A 
reduction in or elimination of mature miRNA levels can occur because of 
defects at any stage of miRNA biogenesis and ultimately leads to the 
inappropriate expression of the miRNA-target oncoprotein. The overall 
outcome might involve increased proliferation, invasiveness or angiogenesis, 
decreased levels of apoptosis, or undifferentiated or de-differentiated tissue, 
ultimately leading to tumour formation. The amplification or overexpression of 
a miRNA that has an oncogenic role would also result in tumour formation. In 
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this situation, increased amounts of a miRNA, which might be produced at 
inappropriate times or in the wrong tissues, would eliminate the expression of a 
miRNA-target tumour-suppressor gene and lead to cancer progression. 
Increased levels of mature miRNA might occur because of amplification of the 
miRNA gene, a constitutively active promoter, increased efficiency in miRNA 
processing or increased stability of the miRNA. 
Figure 3 
 
microRNAs can function as tumour suppressors and oncogenes. a) microRNA in a 
normal tissues. b) microRNA functioning as a tumor suppressor. c) microRNA 
functioning as an oncogene.(Aurora Esquela-Kerscher and Frank J. Slack Nature 
reviews Cancer vol 6 April 2006) 
 
 
 
 
 
1.6 Thyroid cancer 
   Thyroid cancers constitute the most frequent endocrine neoplasia with an 
incidence of one to four new cases per 100000 persons per year, remarkably 
with 2 to 3- fold higher prevalence in women. Diagnosis and treatment of 
thyroid cancer have achieved high levels of medical and technical standard. 
Although some forms of thyroid tumors such as papillary carcinomas show 
quite good prognosis others such as anaplastic tumors have a rather poor 
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prognosis. The thyroid follicular epithelial cells are considered the precursors 
of four forms of thyroid neoplasia: thyroid adenoma, follicular (FTC), papillary 
(PTC) and anaplastic (ATC) carcinoma as well as some variants therefrom 
such as Hurthle cell carcinoma. Another way of classifying thyroid cancers is 
on the basis of their differentiation grade with respect to the TFCs cell from 
which they have originated. Follicular-cell-derived carcinomas are thus broadly 
divided into well-differentiated, poorly differentiated and undifferentiated 
types on the basis of histological and clinical parameters. Well- differentiated 
thyroid carcinoma includes papillary and follicular types (Kondo T et al. 2006). 
The PTC variant is the most frequent (85–90%) type of thyroid malignancy. 
The diagnosis of PTC is based on a series of features such as papillary 
architecture and characteristic nuclear structure that predict the propensity for 
metastasis to local lymph nodes. FTC is defined as a neoplasm, not belonging 
to papillary thyroid carcinoma, with evidence of capsular and/or vascular 
invasion. ATC is defined as an undifferentiated, highly aggressive neoplasm 
with evidence of epithelial differentiation (Kondo T et al. 2006; Gimm O 
2001). Diagnosis of the follicular variant of thyroid carcinoma on the basis of 
morphological and structural features is not always straightforward (Salajegheh 
A et al. 2008). Most well-differentiated thyroid cancers behave in an indolent 
manner and have an excellent prognosis. By contrast, undifferentiated or 
anaplastic thyroid carcinoma is a highly aggressive and lethal tumour. The 
presentation is dramatic, with a rapidly enlarging neck mass that invades 
adjacent tissues. There is currently no effective treatment and death usually 
occurs within 1 year of diagnosis. Poorly differentiated thyroid carcinomas are 
morphologically and behaviourally intermediate between well-differentiated 
and undifferentiated thyroid carcinomas (Kondo T et al. 2006). 
 
 
 
 
1.7 miRNA in Thyroid Cancer 
 
   The first evidence for miRNA involvement in human cancer came from a 
study by Calin et al. (Calin et al. 2002). Deregulation of miRNA expression 
levels emerges as the main mechanism that triggers their loss or gain of 
function in cancer cells. Genomic aberrations might alter miRNA expression, 
since miRNA up-regulation has been associated with genomic amplification  
(O'Donnell et al. 2005), and miRNA down-regulation has been associated with 
chromosomal deletions, point mutations and aberrant promoter methylation 
(Saito et al. 2006).  
Most thyroid carcinomas originate from thyroid follicular cells. The two most 
common cancer types are well-differentiated papillary carcinoma (PC) and 
follicular carcinoma (FC); the latter is further subclassified into conventional 
and oncocytic types. Both PCs and FCs may progress to poorly differentiated 
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carcinoma (PDC) or may completely loose differentiation and transform to 
anaplastic carcinoma (AC). Follicular adenoma (FA) is a benign thyroid tumor 
and can be of either conventional or oncocytic types. Medullary carcinoma 
(MC) originates from the thyroid C cells and accounts for less than 5% of 
thyroid tumors.  Analysis of miRNA expression in normal thyroid tissue and in 
major types of thyroid tumors revealed that majority of known miRNAs were 
expressed in normal thyroid tissues, whereas in thyroid neoplasms 32% of 
miRNAs were found to be consistently upregulated, and 38% were 
downregulated with more than a 2-fold change as compared to normal tissue 
(Nikiforova MN et al. 2008). From the early stages of miRNA discovery, it has 
been known that miRNA expression profiles are tissue specific. A study of all 
major types of thyroid neoplasia showed that miRNA expression profile of C-
cell-derived MCs is significantly different from the miRNA profiles of thyroid 
tumors that originate from follicular cells (Nikiforova MN et al. 2008).  
Most studies have focused on miRNA analysis of PC (Table 1) (He H. et al. 
2005; Tetzlaff MT et al. 2007; Chen YT et al. 2008). Most of the studies have 
identified several miRNAs (miR-146b, miR-221, miR-222, miR-181b, miR-
155, and miR-224) upregulated in PCs. Of interest, many of these miRNAs 
were upregulated as compared to normal thyroid cells and hyperplastic 
nodules; however, one miRNA (miR-181b) was found to be upregulated in 
both thyroid tumors and hyperplastic nodules (Nikiforova MN et al. 2008). A 
study of miRNA expression in PCs with known mutations revealed a strong 
correlation between the miRNA profile and mutational status. Papillary 
carcinomas positive for BRAF, RET/PTC, and RAS mutations, and those with 
no known mutations demonstrated significant differences in the expression of 
certain miRNAs (Nikiforova MN et al. 2008). Although most observation 
reported so far have focused on miRNA expression in papillary thyroid 
carcinomas, we also start to gain insights into miRNA deregulation in follicular 
thyroid carcinomas and adenomas (Nikiforova MN et al. 2008; Weber F. et al. 
2006), anaplastic and poorly differentiated thyroid carcinomas (Nikiforova MN 
et al. 2008; Visone R et al. 2007), and medullary carcinoma (Nikiforova MN et 
al. 2008). (Table 2).  
 
 
 
 
 
 
 
 
 
 
 
 
 
  18 
Table 1 miRNA in papillary thyroid carcinomas  
Deregulated miRNAs 
Number 
of cases 
Specimen 
type 
Profiling 
method miRNAs 
up/down 
regulation 
References 
miR-146,-221,-222,-
21, 220,-181a, -155 Up PC, 15 Frozen tissue Microarray miR-26a-1, -345, -
138, -319 Down 
(He H et all, 
2005) 
PC, 30 Frozen tissue Microarray 
miR-221,-222,-213, 
220,-181b Up 
(Pallante P et 
al, 2006) 
miR-221,-222,-21, -
31, -172, -34a, -213, -
223,-181b, -224 
Up 
PC, 20 FFPE tissue Microarray 
miR-218, -300, -292, 
-345, -30c Down 
(Tetzlaff MT et 
al, 2007) 
PC, 23 Frozen tissue qRT-PCR Array 
miR-187, -221, -222, 
-181b, -146b, -155 Up 
(Nikiforova 
MN et al, 2008) 
 PC, 10 FFPE tissue 
RT-PCR for 
individual 
miRNAs 
miR-146b,-221,-222 Up (Chen YT et al, 2008) 
 
Table 2 miRNA expression in thyroid tumors other than papillary carcinoma  
miRNA deregulation Thyroid tumor type 
miRNA Up/downregulation 
References 
Follicular carcinoma miR-197, -346 Up (Weber F et al, 2006) 
Follicular carcinoma, 
conventional type 
miR-187, -221, -222, -224, -
155 Up 
(Nikiforova MN 
et al, 2008) 
Follicular carcinoma, 
oncocytic type 
miR-221, -224, -203, -183, -
339, -31 Up 
(Nikiforova MN 
et al, 2008) 
Follicular adenoma, 
conventional type 
miR-339, -224, -205, -210, -
190, -328, -342 Up 
(Nikiforova MN 
et al, 2008) 
Follicular adenoma, 
oncocytic type 
miR-221, -224, -203, -183, -
339, -31 Up 
(Nikiforova MN 
et al, 2008) 
Poorly differentiated 
carcinoma 
miR-187, -221, -129, -222, -
146b, -339, -183 Up 
(Nikiforova MN 
et al, 2008) 
miR-222 (<2-folds) Up Anaplastic carcinoma 
miR-30d, 125b, 26°, 30°-5p Down 
(Visone R et al, 
2007) 
Anaplastic carcinoma miR-302c, -205, -137, -187, -214, -155, -224, -222, -221 Up 
(Nikiforova MN 
et al, 2008) 
Medullary carcinoma 
miR-323, -370, -129, -137, -
10a, -124a, -224, -127, -9, -
154 
Up (Nikiforova MN et al, 2008) 
(Nikiforova MN et al. Endocr. Pathol. 2009). 
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1.8 Role of Ras oncogenes   
 
   Constitutive activation of all three Ras oncogenes (H-, K- and N-Ras) is 
known to occur among tumors that originated from the thyroid follicular 
epithelium of the thyroid gland (Lemoine NR et al. 1988). However, there are 
significant discrepancies related to the overall frequency of Ras mutations 
(from 7% to 62%) and their prevalence in specific thyroid tumors (Horie H et 
al. 1995; Pilotti S et al. 1997). Although it is difficult to explain this lack of 
consistency, the mutation screening methods, the selection of patients, and the 
design of individual studies are critical to identify specific association between 
mutational status and clinical or pathological parameters. However in one of 
these studies involving highly specific analysis and performed on a large 
number of patients haboring tumors that included the full spectrum of 
differentiation observed in thyroid cancer of follicular cell derivation, Ras 
mutations were found to be associated with aggressive cancer behaviour, loss 
of differentiated phenotype and with the presence of distant metastasis (Garcia-
Rostan G et al. 2003).  
The presence of Ras mutations in benign tumours suggested that this could 
have been an early event in thyroid tumorigenesis. However, besides the 
considerable variability in the prevalence of Ras mutations in different series of 
thyroid cancers as mentioned above, the high degree of observer variation in 
the diagnosis of follicular adenoma and follicular-variant papillary thyroid 
carcinoma might also explain this finding (Hirokawa M et al. 2002; Lloyd RV 
et al. 2004). It should be considered then that highly specific analysis indicates 
that Ras mutations are more common in poorly differentiated and 
undifferentiated thyroid carcinoma (Table 3), implicating this phenomenon in 
tumour progression rather than in tumor initiation (Kondo T et al. 2006).  
Studies in vivo with transgenic mice have also given valuable information. A 
transgenic mouse line in which a human N-RAS (Gln61Lys) oncogene was 
expressed in thyroid follicular cells under control of the Tg promoter (Tg-N-
RAS) was developed by Santoro’s group. Significantly, Tg-N-RAS mice 
developed thyroid follicular neoplasms; 11% developed follicular adenomas 
and 40% developed invasive follicular carcinomas, in some cases with a mixed 
papillary/follicular morphology. About 25% of the Tg-N-RAS carcinomas 
displayed large, poorly differentiated areas, featuring vascular invasion and 
forming distant metastases in lung, bone or liver (Vitagliano D et al. 2006). 
Ras oncogene in this mouse model appears to contribute both to tumor 
initiation and progression. However level of expression of Ras oncogene 
should be taken into account. It was indeed demonstrated in immortalized rat 
follicular thyroid cells that RAS oncogene induces de-differentiation in a dose-
dependent manner, although TSH-independent growth appears to be induced in 
the presence of both low and high levels of oncogenic RAS expression (De 
Vita G et al. 2005). Thus a reasonable explanation to fit the data would be that 
low levels of Ras oncogene would allow thyroid tumor initiation while higher 
levels of expression or higher activity through additional mutation on the same 
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pathway would allow tumor progression. 
 
 
Table 3. Genetic defects in thyroid cancer. Kondo T. et al. Nature Cancer Reviews 
Vol.6 April 2006.  
 
 
 
1.9 Ras genes 
   The Ras genes were first identified as the transforming oncogenes, 
responsible for the cancer-causing activities of the Harvey (the HRAS 
oncogene) and Kirsten (KRAS) sarcoma viruses, by Edward M. Scolnick and 
colleagues at the National Institutes of Health (NIH). These viruses were 
discovered originally in rats during the 1960s by Jennifer Harvey and Werner 
Kirsten, respectively, hence the name Rat sarcoma. In 1982, activated and 
transforming human Ras genes were discovered in human cancer cells by 
Geoffrey M. Cooper at Harvard, Mariano Barbacid and Stuart A. Aaronson at 
the NIH and by Robert Weinberg of MIT. Subsequent studies identified a third 
human RAS gene, designated NRAS, for its initial identification in human 
neuroblastoma cells. The Ras protein is a monomeric globular protein of 189 
amino acids (21kDa) which is associated with the plasma membrane and which 
binds either GDP or GTP. Ras acts as a molecular switch. When Ras contains 
bound GDP it is in the resting or off position and is "inactive". In response to 
exposure of the cell to certain growth promoting stimuli, Ras is induced to 
exchange its bound GDP for a GTP. With GTP bound, Ras is "switched on" 
and is able to interact with and activate other proteins. In biological process, 
any on switch must be balanced by an off switch. In the case of Ras, the 
protein itself has a very low intrinsic ability to hydrolyze GTP back to GDP, 
thus turning itself into the off state. However, in the case of Ras this intrinsic 
activity is quite low and switching Ras off requires extrinsic proteins termed 
GTPase-activating proteins (GAPs) that interact with Ras and greatly 
  21 
accelerate the conversion of GTP to GDP. Any mutation in Ras which affects 
its ability to interact with GAP or to convert GTP back to GDP will result in a 
prolonged activation of the protein and consequently a prolonged signal to the 
cell telling it to continue to grow and divide. The three human RAS genes 
encode highly related 188 to 189 amino acid proteins. The four mammalian 
Ras isoforms (H-,N- and the two alternative splicing poduct of the K-Ras locus 
K-Ras4A and KRas4B)  are identical in their first 85 aminoacid and have 
>90% identity in the following 80 aminoacid. The principal divergence is 
restricted to the last 24 amino acids which contains signal sequences for post-
translational modifications (Prior IA et al. 2001). A key determinant of Ras 
functioning is indeed post-translational lipid processing of its C-terminal that is 
a prerequisite for membrane recruitment and its consequent biochemical 
activation. The C-terminal CAAX motif is the target of the farnesyl transferase 
enzyme that catalyze the addition of a farnesil isoprenoid lipid followed by 
proteolitic cleavage of AAX sequence (Ras converting enzyme I) and 
carboxymethylation of the now terminal Cys residue by the isoprenylcysteine 
carboxymethyltransferase. An additional signal in the C-terminal is required 
for full membrane recruitment. Prenylated K-Ras-4A and H-ras require a 
further palmitoylation step in which a palmitol moiety is attached to upstream 
C-terminal Cys residues while for prenylated K-Ras-4B a string of positively 
charged Lys residue upstream of the C-terminus is sufficient to mediate its 
anchoring to the membrane (Karnoub AE et al. 2008). The Ras structure 
consist of a hydrophobic core of six stranded β-sheets and 5 α-helices that are 
interconnected by a series of 10 loops. Ras protein has a very inefficient 
GTPase activity by itself, but it interacts with another protein, GAP, which 
enhances GTP hydrolysis. There are two inportant classes of proteins: the G-
nucleotide exchange proteins (GEFs) and the GTPase activating proteins 
(GAPs). The function of GEFs is to promote dissociation of bound GDP and 
thus functioning as a positive regulator of Ras protein. The function of GAPs is 
on the contrary to increase the rate of GTP hydrolysis thus working as a 
negative regulator of Ras protein activity. The coupled activity of both class of 
proteins, tightly controlled within the cells, determines the time window of Ras 
activation (Krauss G ed. 2001; Schubbert S et al. 2007). Regulation of GEFs 
and GAPs activity in the cell can be achieved with very different mechanisms. 
Their activity can be regulated through coupling to membrane receptors or 
through second messangers such as DAG and Ca2+ (Malumbres Met al. 2003; 
Karnoub AE et al. 2008; Downward J 2003). The best characterized example 
of such regulation is the recruitment of the GEF protein Sos by Tyrosine 
Kinase membrane receptors (RTK). RTKs activated by extracellular signals 
recruit Sos to the plasma membrane through the adaptor protein Grb2. Once 
recruited to the membrane, where Ras is localized, Sos protein determines Ras 
activation by promoting dissociation of GDP (Downward J 2003). Mutated Ras 
proteins have been described in a variety of cancer types. It has been shown 
that oncogenic activity correlates with an increased lifetime of the GTP-bound 
Ras form. Oncogenic mutations of Ras proteins are found in particular at 
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position 12, 13 and 61 (Schubbert S et al. 2007). When Gly12 is replaced by 
other amino acids the conformation of the active site does not allow anymore 
the intearaction with upstream positive regulators (GAP) necessary to stimulate 
Ras GTP-ase activity thus fixing Ras in the active GTP-bound form. The Gln 
at position 61 is necessary to stabilize the transition state of the GTP hydrolytic 
reaction. When this aminoacid is substituted the intrinsic GTP-hydrolysis 
activity of Ras is basically abolished and cannot be stimulated further neither 
by GAPs proteins (Krauss G ed. 2001).  
 
 
 
1.10 Ras proteins signal transduction pathways  
 
   Once activated by appropriate signals, the conformational changes induced 
by GTP binding allow the intearaction of Ras protein with its effectors and the 
thus the activation of signal cascades (Figure 4) 
Figure 4 
  
 
Signaling downstream of Ras. The main effectors are shown here. RAF protein 
kinases initiate the mitogen- activated protein (MAP) kinase cascade, which leads to 
ERK activation. Type I phosphoinositide 3-kinases (PI3Ks) generate second-
messenger lipids, such as phosphatidylinositol-3,4,5- trisphosphate, which activate 
numerous target proteins including the survival signalling kinase AKT/PKB. 
RALGDS proteins are guanine nucleotide exchange factors (GEFs) for RAL, a RAS- 
related protein. Downstream targets include Forkhead transcription factors. 
Phospholipase Cε(PLCε) catalyses the hydrolysis of phosphatidylinositol-4,5- 
bisphosphate to diacylglycerol and inositol trisphosphate, resulting in protein kinase C 
(PKC) activation and calcium mobilization from intracellular stores. Downward J. 
Nature Cancer Reviews Vol.3 Jan 2003 
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The MAPK cascade:  The first Ras effector characterized in mammals was the 
Ser/Thr kinase Raf. In mammals there are three Raf isoforms cRaf-1, B-Raf 
and A-Raf (Schreck R et al. 2006; Wellbrock C et al. 2004). Activated Ras 
interacts with Raf kinases thus facilitating plasma membrane association of 
normally citosolic Raf. Full activation of c-Raf-1 and A- Raf is a very complex 
phenomena that requires multiple signals involving both phosphorylation and 
dephosphorylation events, however Ras recruitment to the plasma membrane is 
a necessary pre- requisite for their activation and a sufficient event for B-Raf 
activation (Wellbrock C et al. 2004; Mercer KE et al. 2003). 
Activated Raf kinase phosphorylate and activate the MEK1 and MEK2 dual-
specificity protein kinases. MEK1/2 then phosphorylate and activate ERK1 and 
ER2 MAPKs. Activated ERKs can translocate to the nucleus where they 
phosphorylate and regulate various transcription factors such as Ets family 
transcription factors, ultimately leading to change in gene expression (Zuber J 
et al. 2000; Schulze A et al. 2001). The majority of ERK substrates are nuclear 
proteins and are estimated to comprise over 160 proteins (Yoon S et al. 2006).   
The Raf-MEK-ERK cascade has a key role in Ras normal and neoplastic 
function. It has infact been shown that constututely activated Raf and MEK can 
transform rodent fibroblast and that MEK and ERK are necessary for Ras-
mediated transformation. Further evidences suggesting that mutationally 
activated Ras and Raf are functionally equivalent come from their incidence in 
the same types of human cancers in which mutations of the two genes are 
never overlapping (Repasky GA et al. 2004).  
The PI3K pathway: A second class of Ras effectors is represented by the 
Phosphatidylinositol-3-kinases (PI3K) made up of a regulatory (p85) and a 
catalytic (p110) subunit. Ras mediated PI3K activation is obtained through 
recruitment of PI3K at the plasma membrane through interaction with the p110 
catalytic subunit (Krauss G ed. 2001). Once activated PI3K converts the 
second messenger phosphatidylinositol (4,5) biphosphate (PIP2) into 
phosphatidylinositol (3,4,5) triphosphate (PIP3) which recruits and activates 
the PDK1 kinase which in turns activatre AKT kinase whose activity promotes 
cell proliferation and survival through activation of the mTOR kinase and 
inhibition of FoxO transcription factors (Shaw RJ et al. 2006). The PI3K 
pathway is an important driver of cell proliferation and survival. Numerous 
types of human tumors, both sporadic or arising as a component of a cancer 
predisposition syndrome, shows upregulation of the PI3K pathway.  
The RAL pathway: The Ras-like (Ral) guanyl nucleotide-binding proteins 
RALA and RALB are activated by Ras through its direct interaction with a 
class of GEFs (for example RalGDS) that have biochemical specificity for Ral 
proteins. Thus Ras activation promotes accumulation of Ral proteins in their 
active GTP-bound form. Ral proteins engage multiple effectors and their 
suggested role is to deflect induction of programmed cell death that occour in 
response to aberrant mitogenic signal (Bodemann 2008).   
The number of Ras effectors have been increasing during the years. Some of 
the best characterized additional effectors  are PLCε and  TIAM1. The 
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phospholipase PLCε once activated by Ras cleave PtdIns(4,5)P2 into inositol-
1,4,5-triphosphate (Ins (1,4,5)P3 and diacylglicerol (DAG) promoting releasing 
of Ca2+ and and activation of PKC respecrively. TIAM1 is a Rho GTPase 
family GEF and serves as one rout to activate the Rac and Rho GTPase 
downstream of Ras. Some of the less characterized Ras effectors are AF-6, 
RIN1 and the RASSF proteins (Karnoub AE et al. 2008; Repasky GA et al. 
2004).  
  
 
 
 
1.11 The FRTL-5 thyroid cell line  
 
   The availability of cultured, differentiated thyroid cell lines offers an 
amenable system to study the action of activated Ras proteins on the 
differentiated phenotype of an epithelial cell type. 
The FRTL-5 cell line derive from spontaneous immortalization of a 3 weeks 
old rat epithelial follicular thyroid cells (Ambesi-Impiombato FS et al. 1980). 
These cells retains in culture the expression of all known thyroid differentiation 
markers such as Tg, NIS, TPO and TSHr as well as the thyroid specific 
combination of transcriptiona factors Titf-1, Foxe1, Hhex and Pax8. Despite 
showing some thyroid functional properties such as the ability of concentrate 
iodide and to secrete thyroglobulin, these cells do nor show the charctaristic 
polarization observed in the TFCs and in the standard culture condition do not 
organize into follicular structures. FRTL5 cells rapidly proliferates (duplication 
time about 36h) and their proliferation as well as their differentiation is 
dependent upon TSH presence in the culture medium (Fusco A et al. 1987). 
 
 
 
 
1.12 Transformation of FRTL-5 cells by Ras oncogene  
 
   It was previously shown that Ras oncogene expression in FRTL5 cells 
determines neoplastic transformation. Such transformation involve the 
acquiring of the following properties: TSH- independent growth, anchorage-
independent growth, morphological alterations and the ability of giving rise to 
tumors when injected in nude mice.  Ras oncogene mediated transformation of 
FRTL5 cells is associated with the silencing of thyroid-specific genes such as 
Tg, TPO and NIS (Fusco A et al. 1987; Francis-Lang H et al. 1992).  
Studies aimed to characterized the pathways through which Ras oncogene 
induces transformation and dedifferentiation of FRTL-5 cells have highlighted 
that, though in fibroblasts constitutive activation of MEK (downstream of Raf) 
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and Rac (downstream of PI3K and Tiam1) is sufficient to recapitulate Ras 
effects, in FRTL-5 cells these pathways can reproduce only the oncogenic Ras-
induced proliferative phenotype but do not have consequences on FRTL-5 
differentiation (Cobellis G et al. 1998). It was indeed demonstrated through the 
use of Ras effector domain mutants that Ras oncogene induced 
dedifferentiation requires activation of the Raf/MEK/ERK pathway plus an 
additional uncharacterized pathway (Missero C et al. 2000). Furthermore, it 
was shown that loss of differentiation is an early event, thus not the result of 
chronic exposure to the activated oncogene, induced exclusively by high levels 
of Ras oncogene (De Vita G et al. 2005). 
Ras is one of the oncogenes most frequently activated in Human cancers, 
which, because of its central role in the transduction of extracellular signals, is 
able to re-programme the transcriptome of cells when constitu-tively activated. 
Ras is able to induce aberrant expression of miRNAs during the transformation 
of thyroid epithelial cells (Landgraf et al. 2007). The top-scored upregulated 
miRNA is miR21, a miRNA found overexpressed in several solid and 
hematopoietic malignancies (Krichevs- kyandGabriely 2009). In vitro studies 
have demonstrated that miR21 knockdown in tumor cell lines leads to 
increaseed apoptotic cell death (Seike et al. 2009). Several target mRNAs have 
already been validated for miR21, among which there are at least four known 
tumor suppressors (PTEN, TPM1, PDCD4). The transcription of miR21 
primary RNA is controlled by a conserved upstream enhancer, which has been 
demonstrated to be regulated by gp130-activated Stat3 in myeloma cells, and 
by AP-1 in promyelocitic differentiation induced by TPA (Loffler et al. 2007; 
Fujita et al. 2008). Recently study demonstrate that AP-1activity is necessary 
but not sufficient, for the induction of miR21 triggered by Ras (Talotta et al. 
2009). The induction of miR21 by Ras is mediated by at least two different 
downstream pathways, the Raf-MAPK (mitogen-activated protein kinase) and 
the phosphati-dylinositol 3-kinase (PI3K) pathways (Frezzetti et al. 2010). 
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2. Aim of the Study 
 
 
   H-Ras, K-Ras and N-Ras are three highly related genes that encode for small 
monmeric GTPases involved in the regulation of several biological process as: 
cell proliferation, differentiation, motility and survival. RAS regulated 
pathways are aberrant in most human tumors due both to mutations in Ras 
genes themeselves or Ras effectors. 
Literature emphasizes the key role of miRNAs in cancer development. 
Moreover it has been demonstrated that oncogenes and tumorsuppressors can 
act also by regulating the expression of specific miRNAs. Previous results 
published by Landgraf et al., using the FRTL-5 ER-H-RasV12 inducible system 
highlighted that Ras is able to induce aberrant expression of microRNAs 
during the transformation of thyroid epithelial cells. Taking advantage of the 
inducible system FRTL-5 ER-H-RasV12 we decided to study the miRNAs 
involved in Ras-induced transformation. The aim of my project was to identify 
Ras-regulated miRNAs and study their functional or transcriptional role in 
transformation of thyroid epithelial cells.  
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3. Materials and methods 
 
3.1 Cell culture.  
 
   Rat thyroid follicular FRTL-5-derived cell lines were maintained in Coon’s 
modified F12 medium (EuroClone, Milano, Italy) supplemented with 5% 
newborn bovine serum (HyClone, Logan, UT), penicillin and streptomycin 
100X (EuroClone, Milano, Italy), 20ng/ml Glycyl-histydyl-lysine (SIGMA), 
3.6ng/ml hydrocortisone (SIGMA), 10µg/ml bovine pancreas insulin 
(SIGMA), 5µg/ml Apo-Transferrin Human, 10ng/ml Somatostatin (SIGMA) 
and 0.5mU/ml TSH. "6H medium" refers to above described medium; "5H 
medium" refers instead to above described medium without TSH. Tamoxifen 
treatments, where indicated, were performed by addition of 100 nM 4- 
hydroxytamoxifen (4OHT) (Sigma-Aldrich) to the culture medium.   
NIH 3T3 mouse fibroblasts were maintained in Dulbecco’s Modified Eagle’s 
Medium High Glucose supplemented with 10% fetal bovine serum 
(EuroClone, Wetherby, UK). 
 
 
 
 
 
3.2 Vectors.  
 
   pCEFL miR135a expression vector was generated by PCR amplification 
from thyroid rat genome using the forward primer 
5'ATATAGGATCCCACGTTCCAGAG3' and the reverse primer 
5'ATATAGCGGCCGCTGGAAATGGTT3'. The PCR product was digested 
with BamHI and NotI restriction enzymes and cloned in the pCEFL Neo 
vector.   
The TK-renilla reporter vector was purchased from Promega Corporation 
(phRL-TK); pCMV RasV12. 
pGL3 reporter vectors were generated by PCR amplification from thyroid rat 
genome using: 
pGL3 promoter miR21: 
forward primer 5'TATCCGAGCTCCAAGCTGTTATAATGTACAGG3' and 
the reverse primer 5'TAGTTCTCGAGCACACTGCTGTGGCACAAAG3'.  
pGL3 1Kb Prom mir21 vector was generated by PCR amplification from 
thyroid rat genome using the forward primer 
5'TGAGCTCTTAACTCTCAGGTCACTTGC3' and the reverse primer 
5'TCTCGAGTGCTGTGGCACAAAGAAGAA3'. 
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pGL3 1Kb NO Prom miR21: 
forward primer 5’TATCCGAGCTCTTAACTCTCAGGTCACTTGC3’ and 
the reverse primer 5’TAGTTCTCGAGGTTCCAAGATGTCTGGATAG3’. 
pGL3 624bp Prom miR21: 
forward primer 5’TATCCGAGCTCGAAGGAGGGAAGGGTGTTTA3’ and 
the reverse primer 5’TAGTTCTCGAGCACACTGCTGTGGCACAAAG3’. 
pGL3 870bp Prom miR21: 
forward primer 5’TATCCGAGCTCGCCAACAATTGCGAAGTTGC3’ and 
the reverse primer 5’TAGTTCTCGAGCACACTGCTGTGGCACAAAG3’. 
The PCR products were digested with SacI and XhoI restriction enzymes and 
cloned in the pGL3 SV40 promoter Promega Corporation. 
 
 
 
 
3.3 Transfections. 
 
   All transfections were carried out by the use of FuGene 6 (Roche Molecular 
Biochemicals, Indianapolis, IN) following the manufacturer’s instructions. For 
stable transfection experiments, 2x106 cells were seeded on 100-mm dishes 
24hours prior to transfection and transfected with 4 µg/dish of the indicated 
expression vector. Forty-eight hours later, transfected cells were selected in the 
presence of 1µg/ml of Neomycin (Sigma-Aldrich). After 3 weeks of 
continuous selection single clones were picked, screened for expression of the 
transgene and amplified individually.   
For transient transfections 250*10^3 cells (FRTL-5 cells) or 55*10^3 cells 
(NIH cells) were seeded on 6 multiwell 24hours prior to transfection. 
Transfections were performed with 2 µg/dish of Total DNA consisting of 1µg 
of reporter vector encoding Firefly Luciferase (FF luc); 0.5 µg of pCMV 
RasV12 vector; 0.5 µg of TK-Renilla vector to follow transfection efficiency, 
cotransfecting  vectors or empty vector up to 2 µg.  Transfection medium was 
replaced 15hours later with standard culture medium, supplemented or not with 
additional drugs as indicated in the text, and cells cultured for additional 48 
hours.  
Cells were lysed in 50µL/dish PLB buffer 1x (Promega Corporation) and 
Firefly and Renilla  
Luciferase activity were assayed respectively on 10µL of each sample with the 
“luciferase Assay system” (Promega Corporation) and the “Renilla assay 
system” (Promega Corporation) following manufacturer’s instructions. 
Luminescence was measured with LUMAT LB 9507 luminometer (Berthold 
technologies). Firefly Luciferase activity was normalized on the activity of TK-
renilla vector in order to correct each sample for transfection efficiency. Data 
were obtained from at least two independent experiments with triplicate 
samples.  
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3.4 Chromatin Immuno-Precipitation (ChIP)  
 
3.4.1 Crosslinked chromatin preparation.  
   Briefly 4x106 cells were seeded on 100-mm dishes and cultured 24hours 
with or without additional drugs for the time indicated in the text. At the end of 
the treatment formaldehyde was added to the cells to final 1% for 10 min to 
crosslink the chromatin and the reaction was stopped by adding glycine to a 
final concentration of 0.125 M. Cells were washed twice with PBS, and 
collected in cell lysis buffer (85 mM KCl, 0.5% NP40, 5 mM HEPES pH 8.0) 
(1.5mL /dish) supplemented with a protease inhibitor cocktail (sigma), 
homogenized by Dounce, incubated on ice for 15 min and centrifuged at 3500 
g for 5 min to pellet the nuclei. The pellet was resuspended in nuclear lysis 
buffer (10 mM EDTA, 1% SDS, 50 mM Tris–HCl, pH 8.1) in a ratio 
400µL/107cells. Crosslinked chromatin aliquots were stored at - 80°C or either 
processed directly.  
 
3.4.2 Transcription rate measurement.  
   Transcription rate measurement was performed through an RNA-
polymeraseII-based Chromatin-IP as previously described (232). Crosslinked 
chromatin (400 µL aliquotes) was sonicated on ice with 8 pulses of 30% 
amplitude in a BRANSON 250 sonicator . The average chromatin size of the 
fragments obtained was about 300 bp. The sonified chromatin was centrifuged 
at 14,000 g for 10 min and the supernatants, containing soluble chromatin 
fragments, were diluted 10-fold with dilution buffer (165 mM NaCl, 0.01% 
SDS, 1.1% Triton X, 1.2 mM EDTA, 16.7 mM Tris–HCl, pH 8.0) 
supplemented with protease inhibitor cocktail (Sigma-Aldrich). Diluted 
samples were precleared with 50µL/mL of Salmon sperm DNA/proteinA 
agarose (Upstate) and left 1h under rotation at 4°C. After centrifuging 1 min at 
3000g at 4°C aliquots from the supernatant of each sample (1mL each) were 
incubated with 2.5 µg of RNA pol II antibody (Santa Cruz, sc-899), or as 
negative controls with 2.5 µg of Normal Rabbitt IgG  (Upstate) or in the 
absence of any antibody and left to stay overnight at 4°C under rotation (An 
aliquote of the supernatant  was stored  at 4°C to evaluate INPUT DNA for 
each sample).  The samples were then incubated with 30 µl of Salmon sperm 
DNA/proteinA agarose (Upstate) under rotation for an additional period of 1h. 
Immunocomplex were then recovered and washed as suggested by Upstate.  
Eluition was performed with 2x100 µl of elution buffer (1% SDS, 100 mM 
NaHCO3). Both Immunoprecipitated Chromatin and Input Chromatin were 
incubated at 65°C overnight to reverse formaldehyde crosslinks. DNA 
purification was performed as suggested by Upstate and resuspended in 100µL 
TE buffer. The entire chromatin-IP procedure has been repeated on 
independent tween samples. All obtained DNA samples have been analysed in 
triplicates by Real-Time PCR. Real-time PCR was performed and analysed as 
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described in the previous paragraph using 5µL of DNA as template for each 
reaction. Primer pairs were designed with the Primer express software (Applied 
Biosystem) to amplify a region of 157 bp in length, corresponding to 
Transcription start site (miR21F 5’-agaaagagggagggcagttt-3’/miR21R 5’- 
acactgctgtggcacaaaga-3’). For each sample immunoprecipitated DNA levels 
have been reported as percent of Total INPUT DNA and the average value has 
been calculated on the two independent chromatin IP.   
 
 
 
 
3.5 RNA extraction and Real-Time PCR. 
 
   RNA was extracted using TRIZOL Reagent (Invitrogen) following the 
manufactures instructions. Four micrograms of total RNA from each cell line 
was used as a template for the synthesis of the first strand cDNA, starting from 
random hexamers, using the Superscript II Reverse Transcriptase kit 
(Invitrogen Life Technologies, Carlsbad, CA) according to manufacturer’s 
instructions. Real-Time RT-PCR was conducted on iCycler iQTM Multi-Color 
Real Time PCR Detection System (Biorad) using the iQ SYBR Green 
Supermix (Biorad). Each reaction was carried out in triplicate, using 100ng of 
cDNA as template. Specific primers pair for each gene analyzed were used at 
130nM. Results were analyzed using α-1 tubulin mRNA as reference gene. 
Analysis of results was performed following Real-Time relative-quantitation 
guidelines through the relative Standard curve method as suggested by Applied 
Biosystem. Briefly, amplification efficiency was calculated from triplicates 
relative standard curves for each primer pairs and then used to convert Ct 
values obtained from each reaction into relative-expression units. Data 
obtained in this way were then normalized on the relative-expression of 
reference gene. Statistical analysis was performed on normalized relative-
expression values of each gene.  
The following primers were utilized: 
 
Rno-pri-miR-21 
upper  5’-GCTTTGCTTTAAACCCCGCC-3’ 
lower  5’-TGACTGCAAACCATGATGCTG-3’ Product size: 225bp 
 
TTF1 
Fwd  5’-GGTGCCCTCTGGCCCTATAG-3’ 
Rev  5’-GCTTGTCGATGATGCCCTTTT-3’ Product size: 201bp 
 
TTF2 
Fwd  5’-TTCGTGTCTGCCATGTGAGC-3’ 
Rev  5’-GCCCACGTCCAAAGCAAATC-3’ Product size: 201bp 
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Pax8 
Fwd  5’-GGCCACCAAATCTCTGAGCC-3’ 
Rev  5’-TGGGAATCGATGCTCAGTCG-3’ Product size: 201bp 
 
Tg 
Fwd  5’-GGGACTCGTGTGGTAGGCAC-3’ 
Rev  5’-CAGGTTACAAATCAGTGGCCCT-3’ Product size: 201bp 
 
NIS 
Fwd  5’-TTGTGGTAATGCTCGTTGGC-3’ 
Rev  5’-TCACACCGTACATGGAGAGCC-3’ Product size: 201bp 
 
TSHR 
Fwd  5’-AGGACATGGTGTGTACCCCC-3’ 
Rev  5’-AATCTGCAAAGGCCAGGTTG-3’ Product size: 201bp 
 
TPO 
Fwd  5’-AAGATGCTGAACAGGAACCGG-3’ 
Rev  5’-ATGGAACTCAGCTATGCAGCC-3’ Product size: 201bp 
 
Tubulin 
Fwd  5’-CAACACCTTCTTCAGTGAGACAGG-3’ 
Rev  5’-TCAATGATCTCCTTGCCAATGGT-3’ Product size:201bp 
 
 
 
For microRNA, single stranded cDNA Syntesis was performed using the 
TaqMan MicroRNA Reverse Transcription Kit (Applied Biosystem). The 15µl 
of RT reaction included 0,15µl 100mM dNTPs, 1µl MultiScribe Reverse 
Transcriptase 50U/µl, 1,50µl 10X Reverse Transcription Buffer, 0,19µl RNase 
Inhibitor 20U/µl, 3µl RT primer, 10ng total RNA. The reactions were 
incubated at 16˚C for 30min, 42˚C for 30min, 85˚C for 5min. Real-time PCR 
was performed using a TaqMan MicroRNA Assays protocol on an Applied 
Biosystems 7900HT Fast Real-Time PCR System (P/N: 4351684, Applied 
Biosystems). The 20µl PCR reaction included 1,33µl RT product (minimum 
1:15 diluition from RT reaction, 10µl TaqMan 2X Universal PCR Master Mix 
(No AmpErase UNG), 1µl probe TaqMan microRNA Assay 20X. The 
reactions were incubated in a 96- well plate at 95˚C for 10min, followed by 40 
cycles of 95 ˚C for 15s and 60˚C for 1min. All reactions were run in duplicate. 
The threshold cycle (CT) is defined as the fractional cycle number at which the 
fluorescence passes the fixed threshold. To normalize the expression levels of 
target genes, Let7a has been used.   
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3.6 Protein studies. 
  
   Cells were washed in cold PBS. Total protein extraction was carried out 
using the Tissue Lysis Buffer: 50mM Tris HCl pH 8, 5mM MgCl2, 150mM 
NaCl, 0.5% Deoxycholic Acid, 01% SDS, 1% Triton. Before use to the above 
described buffer were added 100X protease inhibitor cocktail (Sigma) at 1X 
final concentration, 0.5mM PMSF, 5mM sodium orthovanadate (Na3VO4), 
10mM sodium fluoride (NaF), 0.5mM sodium pyrophosphate (Na4P2O7), and 
1mM dithiothreitol (DTT). The lysis buffer for extraction of phosphorylated 
proteins was composed by: HEPES 50mM pH 7.5, 150mM NaCl, 10% 
glycerol, 1% Triton X-100, 1mM EGTA, 1.5mM MgCl2, 10mM NaF, 10mM 
sodium pyrophosphate, 1mM Na3VO4, inhibitor protease cocktail 1X (Sigma). 
Lysis was allowed to continue for 15 min on ice, samples were centrifuged at 
full speed at 4°C for 25 min. Protein concentration was estimated using the 
BCA Protein Assay Kit (Pierce) following manufacturer instruction. For 
monodimensional Western blot analysis 30µg were loaded on SDS-PAGE 
performed using precasted NuPAGE 4-12% Bis-Tris gels (Invitrogen, 
Carlsbad, CA).  
 
 
 
 
3.7 Immunoblot. 
 
   Gels were elettroblotted on PVDF membranes (Immobilon-P, Millipore, 
Bedford, ME) and screened for different antibodies. Rabbit polyclonal 
antibodies against Tg (DACO), Pax8, TTF1 and TTF2, previously produced in 
our laboratory, were used respectively at 1 µg/ml, 0.5 µg/ml, 0.2µg/ml, 0.8 
µg/ml and 0.2 µg/ml. Primary antibodies against GAPDH (ImmunoChemical), 
HRas Specific (Santa Cruz), α1 Tubulin (Sigma), were used as suggested by 
manufactures. Secondary antibodies Mouse IgG Horseradish peroxidase linked 
whole antibody (GE Healthcare), Rabbit IgG Horseradish peroxidase linked 
whole antibody (GE Healthcare) were used as suggested by manufacturers. 
Chemiluminescence was detected using either Pierce ECL Western Blotting 
Substrate (Pierce) or ECLplus Western Blotting Detection system (GE 
Healthcare).  
 
 
 
 
3.8 Proliferation analysis. 
 
   Cell Proliferation rate was determined either by standard growth curve 
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analysis or by Cell Titer 96 AQueous One Solution Cell Proliferation Assay 
(Promega). For standard growth curve 100.000 cells were plated on 60mm 
dishes in 6H medium for 24h hours. Cell Titer 96 AQueous One Solution Cell 
Proliferation Assay is a colorimetric method for determining the number of 
viable cells in proliferation assays. The Cell Titer 96 AQueous One Solution 
Reagent contains a tetrazolium compound (MTS) and an electron coupling 
reagent (PES). 50.000 cells/well were plated in a 96 well, the assay was 
performed adding 20µl of Cell Titer 96 AQueous One Solution directly to 
culture wells, incubate for 2h and then recording absorbance at 490nm with a 
96 well-plate reader. The 96 well plate reader was blanked using fresh culture 
medium. Data were obtained from at least two independent experiments with 
triplicate samples.   
 
 
 
 
3.9 Motility assay. 
 
   Cell migration was estimated by Transwell Assay using the Transwell 
Permeable Support 8 µm polycarbonate membrane 6.5mm Insert provided by 
Corning Incorporated. For transwell assay 50.000 cells were plated in the 
transwell insert and directly treated with the specific medium. After 24h from 
the plating, cells were wiped off from the inner membrane the migrated cells 
were than fixed and stained using a crystal violet and methanol solution (50% 
crystal violet, 10% methanol) for 30min. Quantification of the migrated cells 
was performed destaining the crystal violet solution in 1% SDS solution and 
reading the relative absorbance at 570nm. The data shown are the result of two 
independent experiments performed in triplicate.   
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4. Results and Discussion   
 
   In the inducible FRTL-5 ER-H-RasV12 system, De Vita et al. highlighted that 
TSH-independent proliferation and loss of differentiation are two early and 
direct effects of oncogenic Ras expression. Although the effects of oncogenic 
Ras in thyroid epithelial cells have been extensively studied little still is known 
about the mechanism through which oncogenic Ras is able to promote these 
effects. Our knowledge is constantly increasing about miRNA and their 
potential role in neoplastic transformation. By taking advantage of the 
inducible system FRTL-5 ER-H-RasV12 we decided to study the miRNA 
involved in Ras-induced transformation. 
The aim of my project was to identify miRNAs and study their functional role 
in Ras-induced transformation of thyroid epithelial cells. As a tool we used the 
FRTL-5 ER-H-RasV12 system in which the expression of oncogenic H-RasV12 
is under the control of the mutant ligand binding domain (LBD) of the estrogen 
receptor (ERTM). The TM mutation in the LBD of ER makes the receptor 
sensitive only to tamoxifen (4OHT) and no longer to estrogen (De Vita G. et. 
al. 2005). 
Previous results published by Landgraf et al., using the FRTL-5 ER-H-RasV12 
system highlighted that Ras is able to induce aberrant expression of 
microRNAs during the transformation of thyroid epithelial cells. They cloned 
and sequenced more then 330,000 independent small RNA sequences from 256 
small RNA libraries prepared from 26 distinct organ systems and cell types of 
human and/or rodents, and also re-analyzed some previously described small 
RNA libraries. They examined a restricted thyroid cell line FRTL-5 after the 
induction of a stable, ectopic tamoxifen-regulated RAS oncogene (De Vita et 
al., 2005). Ras induction leads to upregulation of miR-21 after 2 and 7 days 
from 0.3% to 4% and 11% total miRNA content.  
The most strongly regulated miRNA by Ras were validated by Real-Time PCR 
and selected for further functional and transcriptional studies. 
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4.1 Screening of microRNA regulated by Ras. 
 
 
   Recently Landgraf et al. demonstrated that Ras is able to induce aberrant 
expression of microRNAs during transformation of thyroid epithelial cells. We 
decided first to validate the previously described small RNA libraries data by 
Real-Time PCR, and later we selected microRNAs of interest to study their 
functional role in Ras-induced transformation. We measured the level of 
expression of miR15b, miR16, miR27a, miR27b, miR29b, miR99b, miR135a, 
miR135b, miR324-5p in FRTL-5 ER-Ras clone (Cl11) treated with 4OHT for 
24h, 48h, 72h, 96h and 7days. To rule out the possibility that the regulations 
observed could be due to 4OHT treatment, the parental cell line FRTL-5 was 
also treated as FRTL-5 ER-Ras Cl11. We then asked if the microRNAs 
expression profile observed in Cl11 was also associated with chronic thyroid 
epithelial cell transformation. To this aim we measured the level of expression 
of each of previously shown microRNAs in two FRTL-5 clones constitutively 
expressing human H-RasV12 (V27 and V29) (Figure 1).  
Interestingly the screening highlighted that miR135a is slightly down-regulated 
in FRTL-5 ER-Ras Cl11 until 4 days of treatment with 4OHT, then at 7 days of 
treatment the levels of mir135a returned comparable to untreated cells. On the 
other hand miR135a is strongly down-regulated in the chronically transformed 
clones V27 and V29. In order to examine when between 4 and 7 days of 
treatment with 4OHT miR135a starts to rise again we treated FRTL-5 ER-Ras 
Cl11 for 1, 2, 3, 4, 5, 6 and 7days with 4OHT (Figure 2). The same graph also 
shows the levels of expression of miR135a in three chronically transformed 
clones V27, V29 and V39. The results are expressed as fold change of parental 
cell line FRTL-5. 
In order to establish if miR135a down-regulation was necessary for Ras-
induced transformation we decided to over-express the above-mentioned 
microRNA in the chronically transformed clone V29. 
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Figure 1 
 
 
Screening of microRNA Real-Time PCR for 
different microRNAs expression (miR15b, 
miR16, miR27a, miR27b, miR29b miR99b, 
miR135a, miR135b, miR324-5p) in FRTL-5, 
FRTL-5 ER-Ras untreated and treated with 
4OHT for 24h, 48h, 72h, 96h, 7d, and in two 
FRTL-5 cell clones constitutively expressing 
human H-RasV12 (V27 and V29). Results are 
expressed as fold change of the FRTL-5 
parental cell line.  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Figure 2  
 
 
 
 
miR135a levels: Real-Time PCR for miR135a expression in FRTL-5 (blue), FRTL-5 
ER-Ras untreated and treated with 4OHT for 1-2-3-4-5-6-7 days (violet), and in 
chronically transformed FRTL-5 H-RasV12 cells (clone V27, V29 and V39) (green). 
Results are expressed as fold change of the FRTL-5 parental cell line. 
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4.2 Generation of miR135a over expressing clones. 
 
 
   As evident from the screening analysis miR135a was strongly down-
regulated in chronically transformed FRTL-5 H-RasV12 cells (clone V27, V29, 
V39) (Figure 2). To explore a possible functional role to miR135a down-
regulation we decided to stably transfect rat miR135a in FRTL-5 H-RasV12 
clone V29. For this purpose the pre-miR135a sequence was amplified from rat 
genomic sequence and cloned in pCEFL-Neo expression vector between 
BamHI and NotI sites. FRTL-5 H-RasV12 cells were stably transfected with 
pCEFL-Neo-miR135a, and Neo-resistant clones were analyzed for miR135a 
expression by Real-Time PCR (Figure 3). Results are expressed as fold change 
of miR135a expression in FRTL-5 H-RasV12 clone V29 (Figure 3a) and as fold 
change of miR135a expression in FRTL-5 parental cell line (Figure 3b). From 
this analysis the miR135a results over express compared to FRTL-5 H-RasV12 
clone V29, even though the levels of miR135a expression are not comparable 
to miR135a endogen expression in FRTL-5 cells. 
 
 
Figure 3 
 
miR135a levels in FRTL-5 H-RasV12  miR135a clones: Real-Time PCR for miR135a 
expression in different FRTL-5 H-RasV12 miR135a clones. In fig. a) Results are 
expressed as a fold change of miR135a expression in FRTL-5 H-RasV12 clone V29. In 
fig. b) Results are expressed as a fold change of miR135a expression in FRTL-5 
parental cell line. 
 
 
b) 
a) 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4.3 Functional studies of miR135a. 
 
 
   The chronically transformed FRTL-5 H-RasV12 clone V29 is characterized by 
the loss of differentiation (Figure 4a), TSH-independent cell proliferation 
(Figure 4b), and increased cell motility (Figure 4c), all features of transformed 
thyroid epithelial cells. In order to test the possibility that miR135a rescue 
could interfere with at least one of the phenotypes induced by oncogenic Ras 
we proceeded to analyze proliferation, differentiation and cell motility of 
FRTL-5 RasV12 miR135a cells.   
 
Figure. 4 
 
 
Differentiation, Proliferation and Motility of FRTL-5 H-RasV12clone V29. a) Real-
Time PCR for thyroid differentiation markers (TTF1, TTF2, Pax8, Tg, NIS, TPO and 
TSHR) in FRTL-5 cells and FRTL-5 H-RasV12clone V29. Results are expressed in 
fold change of FRTL-5 parental cell line. b) The proliferation rate of FRTL-5 (in red), 
FRTL-5 H-RasV12 (V29) (in blue) was measured by MTT assay. The upper panel 
shows the proliferation in a complete medium (6H) and the lower shows the 
proliferation rate in medium without TSH (5H). c) Cell motility was measured by 
Transwell assay in FRTL-5 (panel upper) and FRTL-5 H-RasV12 clone V29 (panel 
down). Motility was assayed in triplicate. 
a)  b) 
c) 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4.3. 1. miR135a and Proliferation  
 
 
   One of the features of FRTL-5 H-RasV12 cells is the TSH-independent 
proliferation.   
We analyzed the capacity of proliferation of FRTL-5 H-RasV12 miR135a with 
two methods. In the colony assay FRTL-5 H-RasV12 cells were transfected with 
pCEFL-Neo-miR135a and empty vector, and were cultured in complete 
medium (6H) or medium without TSH (5H) to test whether miR135a is able to 
inhibit TSH-independent proliferation promoted by oncogenic H-RasV12 (figure 
5). The colony assay did not highlight any significant differences in the 
proliferation rate of these cells, moreover there were not any differences even 
between proliferation in complete medium (6H) and medium without TSH 
(5H).  
The second method used to test proliferation was MMT assay described in 
materials and methods. We analyzed the proliferation rate of four FRTL-5 H-
RasV12 miR135a clones (A10, A12, B5 and B7), as control we used FRTL-5 
cells and FRTL-5 H-RasV12 clone V29. The assay showed that miR135a 
negatively influenced proliferation when compared to V29. However there 
were no evident differences in the proliferation between the two mediums: 
complete medium (6H) and medium without TSH (5H) (figure 6). Indeed none 
of these clones recovered completely its need of TSH. Suggesting that 
miR135a expression reduces cell proliferation but not specifically Ras-induced 
proliferation.  
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Figure 5 
 
                     
Colony Assay: Colony assay of FRTL-5 H-RasV12 cells (clone V29) transfected with 
pCEFL-miR135a expression vector and empty vector. The cells were cultured in 
complete medium (6H) or medium without TSH (5H). Plates were treated with crystal 
violet solution for colonies visualization. 
 
 
 
Figure 6 
 
 
FRTL-5 HRasV12 miR135a proliferation. The proliferation rate of FRTL-5, FRTL-5 
H-RasV12 (V29) and FRTL-5 H-RasV12 miR135a clones (A10, A12, B5, B7) was 
measured by MTT assay as described in materials and methods. In panel a) the 
proliferation in a complete medium (6H) is shown. In panel b) the proliferation rate in 
medium without TSH (5H) is shown. 
 
 
 
 
 
 
 
a)  b) 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4.3. 2. miR135a and Differentiation.  
 
 
   Oncogenic Ras induces the loss of differentiation of FRTL-5 cells. Indeed in 
V29 clone we can observe a significant decrease at both the mRNA and protein 
(where shown) level of several thyroid differentiation markers: thyroid 
transcription factors TTF1, TTF2, Pax8, thyroglobulin (Tg), TSH receptor 
(rTSH), sodium iodide symporter (NIS) and the thyroperoxidase (TPO). 
In order to establish if miR135a was able to affect the loss of differentiation 
induced by oncogenic Ras the state of differentiation of FRTL-5 H-RasV12 
miR135a clones was analyzed both at the mRNA and protein level.  
By Real-Time PCR we measured TTF1, TTF2, Pax8, Tg, NIS, TSHr and TPO 
mRNA in four FRTL-5 H-RasV12 miR135a clones (A10, A12, B5 and B7 
clones) expressing different levels of miR135a. The results were compared 
with the level of expression in both V29 clone and parental FRTL-5 cells 
(figure 7). Apparently in none of these clones there is evidence of a significant 
rescue of the above-mentioned thyroid differentiation markers. Similar results 
were obtained at the protein level by western blot. Indeed miR135a expression 
is not able to interfere with TTF1, TTF2, Pax8 and Tg protein down-regulation.  
In conclusion, we do not have evidence that supports the hypothesis of an 
involvement of miR135a in a loss of differentiation induced by Ras. 
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Figure 7  
 
 
Differentiation in FRTL-5 H-RasV12 miR135a clones: Real-Time PCR for TTF1, 
TTF2, Pax8, Tg, NIS, TSHR and TPO in FRTL-5, FRTL-5 H-RasV12 and FRTL-5 H-
RasV12 miR135a clones. TTF1, TTF2, Pax8 and Tg were analyzed also with western 
blot analysis. As control GAPDH was used as loading control. 
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4.3. 3. miR135a and Cell Motility.  
 
 
   Since it is known that oncogenic Ras is involved in cell motility control we 
investigated also if miR135a can alterate the Ras-induced cell motility of 
FRTL-5 cells. To this purpose we tested the motility of four FRTL-5 RasV12 
miR135a clones (A10, A12, B5 and B7) and we compared to both V29 and 
parental FRTL-5 cells. Cell migration was estimated by Transwell Assay 
described in materials and methods. Migrated cells were stained with crystal-
violet solution (figure 8a). Quantification of migrated cells was obtained by 
destining with 1% SDS and reading the relative absorbance at 570nm (Figure 
8b). 
In FRTL-5 parental cells line no motility was observed, they were used as 
negative control of migration, in FRTL-5 transformed by Ras (FRTL-5 H-
RasV12) cells migration is visible indeed this clone was used as positive control 
of migration. In FRTL-5 H-RasV12 miR135a clones migration is slightly 
reduced respect to FRTL-5 H-RasV12 (V29 clone). Moreover it seems that cell 
motility impairment is related to the amount of miR135a, indeed A10 and A12, 
that express on higher amount of miR135a respect to B5 and B7 clones, shown 
a more significant reduction of cell motility (Figure 8). 
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Figure 8  
 
 
 
 
 
 
 
 
 
 
FRTL-5 H-RasV12 miR135a Cell Motility. Cell motility was measured by Transwell 
assay. Motility was assayed in triplicate. In panel a) were shown the relative transwell 
after crystalviolet the parental cell line FRTL-5; FRTL-5 H-RasV12 (V29); FRTL-5 H-
RasV12 miR135a clones (A10, A12, B5, B7). b) Quantification of the migrated cells 
performed with crystal violet solution. The results are expressed as relative 
absorbance at 570nm. 
 
a) 
b) 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   In conclusion the chronically transformed FRTL-5 H-RasV12 clone V29 is 
characterized by loss of differentiation, TSH-independent cell proliferation, 
and increased cell motility, all features of transformed thyroid epithelial cells. 
These cells express very low levels of miR135a. We tested the possibility that 
miR135a rescue could interfere with at least one of the phenotypes induced by 
oncogenic Ras. To this purpose we analyzed proliferation, differentiation and 
cell motility of FRTL-5 RasV12 miR135a cells. We observed a moderate 
reduction of proliferation and migration in miR135a clones compared to 
FRTL-5 RasV12. This reduction of proliferation and migration are not so strong, 
for this reason we decided to analyze the over-expression of the microRNA in 
exam in miR135a clones compared to FRTL-5 parental cell line by Real-Time 
PCR analysis. Results are expressed as fold change of miR135a expression in 
FRTL-5 parental cell line (Figure 3b). From this analysis results, none of the 
analyzed clones express miR135a at a level at least comparable to the 
endogenous miR135a in the parental FRTL-5 cells. 
This observation leads to the possibility that the mild effects observed on 
proliferation and migration of miR135a clones could be a consequence of the 
low over-expression of miR135a achieved. A possible explanation of this 
phenomenon could be that co-expression of oncogenic Ras and high levels 
miR135a is not compatible with survival, leading to a selection of clones that 
express only low levels of miR135a. 
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4.4 Regulation of miR-21 is cell-type specific.  
 
 
   Once established that oncogenic Ras is able to promote miR21 expression in 
an epithelial system we asked if this regulation was cell-type specific. To this 
purpose we used NIH 3T3 fibroblasts cells stably transfected with the inducible 
oncogene ER-Ras and tested the induction of miR21 after treatment with 
4OHT. We thus, performed a time course of miR-21 induction in FRTL-5 ER-
Ras cells compared with NIH ER-Ras cells. Cells where treated with 4OHT for 
24h, 48h and 72h (Figure 9), results are expressed both as fold change of the 
control untreated cells (NT) (Figure 9a) and as relative values normalized for 
the expression of let-7a (Figure 9b). 
The results highlight that even though the two cell lines have a different basal 
level of miR21, in NIH ER-Ras cells 4OHT treatment does not lead to a 
significant increase of miR21, suggesting that Ras-induced miR21 up-
regulation is cell-type specific. 
 
Figure 9 
 
 
 
 
Time course of miR21 expression: NIH ER-Ras and FRTL-5 ER-Ras cells have been 
untreated and treated with 4OHT for 24h, 48h and 72h. Then total RNA was extracted 
and miR-21 expression was measured by Real-Time PCR as described in materials 
and methods. a) Results are expressed as fold change of the control treated with 
EtOH. b) Results are expressed as absolute values. 
 
 
 
 
 
a) 
b) 
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4.5 miR21 induction by Ras in FRTL-5 is mediated by transcriptional 
regulation. 
 
 
   Once established the effects of oncogenic Ras on miR21 expression the next 
step was to study the mechanism through which this regulation takes place. 
We investigated if the induction of miR21 after Ras activation is a 
transcriptional phenomenon. For this purpose we measured, by Real-Time 
PCR, the levels of primiR21, using both the FRTL-5 ER-Ras and NIH ER-Ras 
cells. 
We performed a time course of primiR-21 induction in FRTL-5 ER-Ras cells 
compared with NIH ER-Ras cells. Both inducible systems where treated with 
4OHT for 24h, 48h and 72h (Figure 10). Results are expressed as fold change 
of the untreated control cells (Figure 10a) relative values normalized for the 
expression of tubulin (Figure 10b).  
The kinetics of induction of primiR-21 expression by Ras is different in the 
two cell systems: in FRTL-5 ER-Ras cells induction of primiR-21 is 
significantly higher compared to NIH ER-Ras cells. primiR21 expression 
levels in NIH ER-Ras cells are similar to untreated NIH ER-Ras cells. 
primiR21 expression in FRTL-5 ER-Ras is strongly induced already after 24h 
of treatment with 4OHT (Figure 10). This data suggests that primiR21 
induction by Ras in FRTL-5 cells is a transcriptional phenomenon. 
To confirm this data we performed a Chromatin Immuno-precipitation (ChIP) 
on FRTL-5 ER-Ras cells. We measured RNA polymerase II occupancy of the 
miR21 promoter sequence in FRTL-5 ER-Ras cells after activation of Ras 
oncoprotein with 4OHT treatment for 24h (Figure 11). To measure the levels 
of RNA Pol II associated with miR21 promoter we used a specific antibody 
against RNA Pol II  (RNPII) as negative control Chromatin-IP was performed 
in absence of antibody (No Ab). Immuno-precipitated DNA was measured by 
Real-Time PCR and was reported as percentage of Input DNA. This assay 
shows that the amount of RNA Polymerase II bound to miR21 promoter 
increases after oncogenic Ras expression. These results are consistent with 
primR21 increase previously observed and indicate that oncogenic Ras rapidly 
activates miR21 transcription. 
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Figure 10 
 
 
 
 
Time course of pri-miR21 expression: NIH ER-Ras and FRTL-5 ER-Ras cells have 
been untreated and treated with 4OHT for 24h, 48h, 72h. Then total RNA was 
extracted and pri-miR-21 expression was measured by Real-Time PCR as described in 
materials and methods. a) Results are expressed as fold change of the control treated 
with EtOH. b) Results are expressed as absolute values. 
 
 
Figure 11 
 
 
miR21 transcription measurement: FRTL-5 ER-Ras were treated with 4OHT for 24h. 
miR21 transcription was measured by performing a Chromatin-IP with RNA 
Polimerasi II antibody (RNPII) as described in materials and methods. As negative 
control a Chromatin-IP was performer in the absence of any antibody (No Ab). 
Immuno-precipitaded DNA was measured by Real-Time PCR and is reported as 
percentage of Input DNA. 
b) 
a) 
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4.6 miR21 promoter is responsive to oncogenic Ras expression. 
 
 
   Once established that oncogenic Ras is able to promote miR21 expression in 
epithelial cells while unable to induce it in fibroblasts, we decided to verify if 
even the promoter of miR21 was sensitive to oncogenic Ras expression in a 
cell-type specific manner. Recently the miR21 putative promoter region was 
identified (Fujita et al. 2008). It is known that this region is responsive to 
oncogenic Ras in FRTL-5 cells (Talotta et al. 2009). We tested if the regulation 
of this promoter by oncogenic Ras was cell-type specific. To this purpose we 
used NIH 3T3 fibroblasts cells stably transfected with the inducible system 
ER-Ras and tested the activation of miR21 promoter after treatment with 
4OHT (Figure 12a). The same experiment was performed co-transfecting 
miR21 promoter with the pCMV RasV12 expression vector in the FRTL-5 and 
NIH 3T3 parental cell line (figure 12b). Our data suggests that miR21 promoter 
is responsive to Ras in both cellular line but its activation is lower in NIH 3T3 
cells. 
Figure 12 
 
 
 
 
 
miR21 promoter responsive to Ras activation. Luciferase assay for tested the 
activation of miR21 promoter by oncogenic Ras. Luciferase reporters were 
transfected with an internal control pRLTK-Vector. For Ras induction a) 100nM of 
Tamoxifen (4OHT) was added to the cells 24h after transfection, and luciferase 
activity was measured after 48h of induction. b) pCMV RasV12 vector and empty 
vector were co-transfected and luciferase activity was measured after 48h of 
transfection. 
a) 
b) 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4.7 Identification of miR21 regulatory regions responsive to Ras. 
 
 
   We were interested in the identification of potential regulatory regions, aside 
from the promoter already identified, responsive to oncogenic Ras. To answer 
this question, we first cloned a region of 1kb located upstream of pri-miR21. 
This region was comprehensive of the already identified promoter. We then 
prepared three reporter vectors in which we cloned three different deletions of 
the 1kb region (Figure 13). Each construct was tested by luciferase assay in 
both FRTL-5 cells and NIH 3T3 cells in absence or presence of oncogenic Ras.  
In FRTL-5 cells Ras was still able to induce luciferase expression in all 
deletion constructs even if with a different intensity compared to promoter 
alone (figure 14a). Interestingly in NIH3T3 cells even though we can still 
observe an effect of oncogenic Ras on all of the deletion constructs, the 
activation is not comparable to the one observed in FRTL-5 cells (figure 14b). 
Only the 624bp construct showed a different behavior, indeed oncogenic Ras is 
able to induce its expression only in NIH3T3 cells.  
We focused our attention on the 1kb construct since its behavior in presence of 
oncogenic Ras is in agreement with the different trend of expression of both 
precursor and mature miR21 observed in FRTL-5 and NIH3T3 cells in absence 
or presence of oncogenic Ras. Until now our data strongly suggested that the 
upregulation of miR21 by oncogenic Ras can be cell type specific. To test this 
hypothesis we analyzed the regulation of both miR21 promoter and 1kb 
construct in presence of oncogenic Ras also in Rat2 cells (figure 15). FRTL-5, 
NIH3T3 and Rat2 cells were all co-transfected with either promoter or 1kb 
construct in presence of pCMV or pCMV H-RasV12. The results obtained, 
highlighted once again that the Ras-induced activation of both promoter and 
the 1kb construct is clear only in FRTL-5 cells.  
Figure 13 
 
 
Schematic reppresentation of 
deletion constructs: In figure a 
graphic reppresentation of 
deletion constructs of miR21 
putative regulatory region is 
shown. 1kb: miR21 promoter 
plus a sequence of 647bp located 
upstream of promoter; 870bp: 
miR21 promoter plus a sequence 
of 449bp located upstream of 
promoter; 624bp: miR21 
promoter plus a sequence of 
203bp located upstream of 
promoter; 1Kb No Prom: a 
sequence of 647 bp located 
upstream of promoter 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Figure 14 
 
 
 
 
 
Putative regulatory region of miR21 responsive to Ras oncogene: Luciferase assay 
of deletion constructs of miR21 putative responsive region to Ras oncogene in a) 
FRTL-5 cells and b) NIH 3T3 cells. Luciferase reporters were transfected with an 
internal control pRLTK-Vector. For Ras induction 0,5ug of pCMV RasV12 vector and 
empty vector were co-transfected and luciferase activity was measured after 48h of 
transfection. 
 
 
a) 
b) 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Figure 15 
 
 
 
Identification of a novel 1kb region induced by oncogenic Ras in thyroid epithelial 
cells: Luciferase assay of miR21 promoter and 1kb deletion construct are shown. 
FRTL-5 cells, NIH 3T3 and Rat2 fibroblasts were all co-transfected with either 
promoter or 1kb construct in presence of pCMV or pCMV H-RasV12. Luciferase 
reporters were transfected with an internal control pRLTK-Vector. Luciferase activity 
was measured after 48h of transfection. 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 5. Conclusion 
 
 
   Previous results highlighted that Ras is able to induce aberrant expression of 
microRNAs during the transformation of thyroid epithelial cells. We decided to 
study the miRNAs involved in Ras-induced transformation. The aim of my 
project was to identify Ras-regulated miRNAs and study their role in 
transformation of thyroid epithelial cells. From our studies miR135a and 
miR21resulted strongly regulated by Ras: miR135a is down-regulated while 
miR21 is upregulated. 
The functional studies performed on FRTL-5 H-RasV12 miR135a 
overexpressing clones highlighted that even though the rescue of miR135a is 
not sufficient to re-establish the TSH dependency, we can still observe a 
significant reduction of the proliferation rate when compared to the parental 
FRTL-5 H-RasV12 cells. Also for what concerns cell migration miR135a 
overexpressing clones display a light reduction of the motility when compared 
to FRTL-5 H-RasV12 cells. These promising but mild effect could be due to the 
low level of over expression of miR135a obtained in FRTL-5 H-RasV12 cells 
when compared with wild type FRTL-5 cells. Our hypothesis is that high levels 
of miR135a and oncogenic Ras are not compatible. For this reason we are 
currently stably transfecting miR135a in FRTL-5 ER-Ras cells where 
oncogenic Ras expression is strictly dependent on 4OHT treatment. 
For what concerns miR21 regulation both real time analysis of the miR21 
precursor (primiR21) and PolII chromatin immunoprecipitation suggests that 
the upregulation of miR21 induced by oncogenic Ras occurs at a 
transcriptional level. Moreover we were not able to detect any significant Ras-
dependent upregulation of miR21 in NIH3T3 cells suggesting a possible cell-
type specific regulation. 
Furthermore the analysis of the upstream region of the miR21 promoter led us 
to the identification of a novel 1kb region induced by oncogenic Ras. 
Interestingly this region seems to be positively regulated by Ras only in FRTL-
5 indeed both in Rat2 and NIH3T3 cells Ras is not able to induce the 1kb 
region. In conclusion our results strongly suggest that Ras is promoting miR21 
at a transcriptional level and that this regulation could be cell-type specific.  
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